肝细胞生长因子在乳腺癌新辅助化疗前后的变化及其临床意义

Changes and clinical significance of hepatocyte growth factor before and after neoadjuvant chemotherapy for breast cancer

目的探究肝细胞生长因子(HGF)在乳腺癌新辅助化疗(NAC)前后的表达变化及其与NAC疗效联系。方法收集2014年1月至2018年12月收治的120例行2~4周期EC新辅助化疗方案的乳腺癌患者临床资料,采用免疫组织化学法检测NAC前后ER、PR、HER-2、Ki-67及HGF的表达情况。使用SPSS 25.0统计软件分析,各亚组乳腺癌中HGF的阳性表达率等计数资料以例数或率(%)表示,行χ^(2)检验,P<0.05差异有统计学意义。结果HGF在乳腺癌中的总体阳性表达率为86.7%(104/120);Luminal B型、HER-2过表达型及三阴型乳腺癌的HGF阳性表达率分别为82.1%(23/28)、86.4%(38/44)、89.6%(43/48),差异无统计学意义(P>0.05);NAC总有效率75.0%(90/120),HGF在NAC无效乳腺癌的阳性表达率为83.3%(25/30),其与NAC前HGF的阳性表达率相比差异无统计学意义(P>0.05);HGF在NAC后有效的Luminal B型、HER-2过表达型以及三阴型乳腺癌的阳性表达率分别为42.9%(6/14)、20.6%(7/34)、11.9%(5/42),其与NAC前HGF的阳性表达率相比差异有统计学意义(P<0.05)。结论HGF在乳腺癌组织中表达较高,与分子亚型无明显关联,HGF有可能作为乳腺癌NAC临床疗效的预测标志物。

Objective To investigate the changes of the expression of hepatocyte growth factor(HGF)before and after neoadjuvant chemotherapy(NAC)for breast cancer and to analyze the efficacy of NAC.Methods From January 2014 to December 2018,clinical data of 120 breast cancer patients received NAC with 2-4 cycle EC regimen were analyzed retrospectively.ER,PR,HER-2,Ki-67 and HGF were detected by immunohistochemistry before and after NAC.Statistical software SPSS 25.0 were used for data analysis,and P<0.05 was considered statistically significant.Results The overall positive expression rate of HGF in breast cancer was 86.7%(104/120);and the positive rates of Luminal B type,HER-2 overexpression type and triple negative breast cancer were 82.1%(23/28),86.4%(38/44)and 89.6%(43/48)respectively,with no significant difference in the expression of HGF between different breast cancer subtypes(P>0.05);The overall effective rate of NAC was 75.0%(90/120)while the positive expression rate of HGF in NAC ineffective breast cancer was 83.3%(25/30).There was no significant difference between groups in terms of the positive expression rate of HGF before NAC(P>0.05);The positive expression rate of HGF in NAC effective breast cancer for Luminal B type,HER-2 overexpression type and triple negative breast cancer were 42.9%(6/14),20.6%(7/34),and 11.9%(5/42)respectively,with significant difference in terms of the positive expression rate of HGF before NAC(P<0.05).Conclusion HGF is highly expressed in breast cancer tissues and has no obvious relationship with molecular subtypes.HGF is expected to be a predictor for the efficacy of NAC to breast cancer.